OpGen Announces Closing of $12 Million Public Offering

Genetics Investing

OpGen (NASDAQ:OPGN) announces the closing of its previously announced public offering of 2,841,152 units at $3.25 per unit and 851,155 pre-funded units at $3.24 per pre-funded unit, raising gross proceeds of approximately $12 million. As quoted in the press release: “We are very pleased to have completed this offering with both new and existing stockholders, and look …

As quoted in the press release:

“We are very pleased to have completed this offering with both new and existing stockholders, and look forward to continuing the development of our Acuitas AMR Gene Panels, as well as additional efforts to improve patient care and tackle the problem of multidrug antibiotic resistance,” said Evan Jones, chairman and chief executive officer of OpGen. “We expect that the capital from this raise will fund our planned operating activities into 2019 and allows us to focus on executing our growth strategy.”

Click here to read the full press release.

opgen patient public offering us Genetics Investing